Cargando…
Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study
INTRODUCTION: Among white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. Meanwhile, there has also been a significant improvement in 5-year survival among patients with melanoma. This population-based cohort study investigates the five-y...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634953/ https://www.ncbi.nlm.nih.gov/pubmed/34868928 http://dx.doi.org/10.3389/fonc.2021.737399 |
_version_ | 1784608213378793472 |
---|---|
author | Buja, Alessandra Bardin, Andrea Damiani, Giovanni Zorzi, Manuel De Toni, Chiara Fusinato, Riccardo Spina, Romina Vecchiato, Antonella Del Fiore, Paolo Mocellin, Simone Baldo, Vincenzo Rugge, Massimo Rossi, Carlo Riccardo |
author_facet | Buja, Alessandra Bardin, Andrea Damiani, Giovanni Zorzi, Manuel De Toni, Chiara Fusinato, Riccardo Spina, Romina Vecchiato, Antonella Del Fiore, Paolo Mocellin, Simone Baldo, Vincenzo Rugge, Massimo Rossi, Carlo Riccardo |
author_sort | Buja, Alessandra |
collection | PubMed |
description | INTRODUCTION: Among white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. Meanwhile, there has also been a significant improvement in 5-year survival among patients with melanoma. This population-based cohort study investigates the five-year melanoma-specific survival (MSS) for all melanoma cases recorded in 2015 in the Veneto Tumor Registry (North-Est Italian Region), taking both demographic and clinical-pathological variables into consideration. METHODS: The cumulative melanoma-specific survival probabilities were calculated with the Kaplan-Meier method, applying different sociodemographic and clinical-pathological variables. Cox’s proportional hazards model was fitted to the data to assess the association between independent variables and MSS, and also overall survival (OS), calculating the hazard ratios (HR) relative to a reference condition, and adjusting for sex, age, site of tumor, histotype, melanoma ulceration, mitotic count, tumor-infiltrating lymphocytes (TIL), and stage at diagnosis. RESULTS: Compared with stage I melanoma, the risk of death was increased for stage II (HR 3.31, 95% CI: 0.94-11.76, p=0.064), almost ten times higher for stage III (HR 10.51, 95% CI: 3.16-35.02, p<0.001), and more than a hundred times higher for stage IV (HR 117.17, 95% CI: 25.30-542.62, p<0.001). Among the other variables included in the model, the presence of mitoses and histological subtype emerged as independent risk factors for death. CONCLUSIONS: The multivariable analysis disclosed that older age, tumor site, histotype, mitotic count, and tumor stage were independently associated with a higher risk of death. Data on survival by clinical and morphological characteristics could be useful in modelling, planning, and managing the most appropriate treatment and follow-up for patients with CMM. |
format | Online Article Text |
id | pubmed-8634953 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86349532021-12-02 Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study Buja, Alessandra Bardin, Andrea Damiani, Giovanni Zorzi, Manuel De Toni, Chiara Fusinato, Riccardo Spina, Romina Vecchiato, Antonella Del Fiore, Paolo Mocellin, Simone Baldo, Vincenzo Rugge, Massimo Rossi, Carlo Riccardo Front Oncol Oncology INTRODUCTION: Among white people, the incidence of cutaneous malignant melanoma (CMM) has been increasing steadily for several decades. Meanwhile, there has also been a significant improvement in 5-year survival among patients with melanoma. This population-based cohort study investigates the five-year melanoma-specific survival (MSS) for all melanoma cases recorded in 2015 in the Veneto Tumor Registry (North-Est Italian Region), taking both demographic and clinical-pathological variables into consideration. METHODS: The cumulative melanoma-specific survival probabilities were calculated with the Kaplan-Meier method, applying different sociodemographic and clinical-pathological variables. Cox’s proportional hazards model was fitted to the data to assess the association between independent variables and MSS, and also overall survival (OS), calculating the hazard ratios (HR) relative to a reference condition, and adjusting for sex, age, site of tumor, histotype, melanoma ulceration, mitotic count, tumor-infiltrating lymphocytes (TIL), and stage at diagnosis. RESULTS: Compared with stage I melanoma, the risk of death was increased for stage II (HR 3.31, 95% CI: 0.94-11.76, p=0.064), almost ten times higher for stage III (HR 10.51, 95% CI: 3.16-35.02, p<0.001), and more than a hundred times higher for stage IV (HR 117.17, 95% CI: 25.30-542.62, p<0.001). Among the other variables included in the model, the presence of mitoses and histological subtype emerged as independent risk factors for death. CONCLUSIONS: The multivariable analysis disclosed that older age, tumor site, histotype, mitotic count, and tumor stage were independently associated with a higher risk of death. Data on survival by clinical and morphological characteristics could be useful in modelling, planning, and managing the most appropriate treatment and follow-up for patients with CMM. Frontiers Media S.A. 2021-11-16 /pmc/articles/PMC8634953/ /pubmed/34868928 http://dx.doi.org/10.3389/fonc.2021.737399 Text en Copyright © 2021 Buja, Bardin, Damiani, Zorzi, De Toni, Fusinato, Spina, Vecchiato, Del Fiore, Mocellin, Baldo, Rugge and Rossi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Buja, Alessandra Bardin, Andrea Damiani, Giovanni Zorzi, Manuel De Toni, Chiara Fusinato, Riccardo Spina, Romina Vecchiato, Antonella Del Fiore, Paolo Mocellin, Simone Baldo, Vincenzo Rugge, Massimo Rossi, Carlo Riccardo Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
title | Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
title_full | Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
title_fullStr | Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
title_full_unstemmed | Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
title_short | Prognosis for Cutaneous Melanoma by Clinical and Pathological Profile: A Population-Based Study |
title_sort | prognosis for cutaneous melanoma by clinical and pathological profile: a population-based study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634953/ https://www.ncbi.nlm.nih.gov/pubmed/34868928 http://dx.doi.org/10.3389/fonc.2021.737399 |
work_keys_str_mv | AT bujaalessandra prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT bardinandrea prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT damianigiovanni prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT zorzimanuel prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT detonichiara prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT fusinatoriccardo prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT spinaromina prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT vecchiatoantonella prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT delfiorepaolo prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT mocellinsimone prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT baldovincenzo prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT ruggemassimo prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy AT rossicarloriccardo prognosisforcutaneousmelanomabyclinicalandpathologicalprofileapopulationbasedstudy |